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Summary
We have examined the nature and localization of somatic mutations in three tc transgenes cloned
from IgG-secreting hybridomas. All of the mutations identified were single base substitutions.
Mutations were localized to the variable (V) region and its flanking sequences. In every case,
the nuclear matrix association region, K enhancer, and C gene were spared. These data indicate
that the rearranged « gene contains the necessary sequences for targeting ofthe mutation process,
and suggest that the observed localization of mutations to the V region reflects the inherent
specificity of this mutation process.
S
omatic mutation of Ig V genes after antigenic stimula-
tion is an important mechanism responsible for diver-
sification of V genes (reviewed in references 1 and 2). The
mutations are generally single base substitutions and are local-
ized to the V region and its flanking sequences (3, 4). The
mechanism responsible for introduction of these mutations
is unclear. In the chicken, it appears that upstream V or VD
pseudogenes can function as potential donor sequences for
H and L chain V gene conversions (5-7). However, in mam-
malian species, there is little evidence in support ofa significant
role for gene conversion (8, 9).
The overall frequency of mutations has been found to be
similar for both productively and nonproductively rearranged
V genes (10). There appears to be at least a 10-fold reduction
in frequency of mutations in partially assembled V regions,
i.e., genes arrested at the DJ stage (11, 12). Few (13), if any,
somatic mutations are seen in germline V genes (14). Thus,
rearrangement ofV genes seems to be important for targeting
the mutator machinery and may be integral to its complete
activation as well.
In an effort to examine the role of a rearrangement event
in the acquisition of somatic mutations, we introduced a rear-
ranged tc gene cloned from the myeloma MOPC-167 into
the germline of mice (15). Analysis of hybridomas generated
from these mice revealed the following: (a) ongoing rear-
rangement is not required for the introduction of somatic
mutations; (b) targeting of the Ig transgeneby the "mutator"
is independent of its chromosomal location; and (c) based
on preliminary sequence analysis, mutations were present in
the transgene V regions, but not in the C regions (16). Pre-
liminary evidence for somatic hypermutation of an H chain
transgene has also been obtained (17).
In the present study, we examined the nature and localiza-
tion of somatic mutations in three K transgenes cloned from
IgG-secreting hybridomas. Since the transgenes are present
in multiple copies in these transgenic mice, this allows ex-
amination of the overall integrity of the somatic mutation
process under conditions where selective pressures to pro-
duce functional Ig L chains have been greatly reduced.
Materials and Methods
Hybridomas.
￿
The hybridomas 3A1, CE9, and CF2 were gener-
ated from splenic B cells in mice carrying a rearranged K transgene
after hyperimmunization with phosphorylcholine (PC)'-keyhole
limpet hemocyanin (16). 3A1 was generated from mouse line 194-
2, which contains threecopies ofthe K transgene (unpublished ob-
servation) along with the complete pUC18 vector, while CE9and
CF2 were generated from the 233-8 line that carries -13 copies
of the K transgene with -150 by of pUC18. All of the hybridomas
transcribe both the T15V gene and the K transgene, and secrete
IgG that binds PC (16). They were selected for transgene mutation
analysis because their endogenous V gene was mutated, thus,
they were known to have undergone a somatic hypermutation
event (16).
Cloning and Sequencing.
￿
The construction of partial genomic
libraries of 3A1, CE9, and CF2, and subcloning of 4.8-kb BamHI
fragments containing the V and C regions ofthe K transgenes has
been described previously(16). The entire 4.8 kb ofgenomic clone
pl-7 isolated from hybridoma CE9was subcloned as fragments aver-
aging 400by in length into Bluescript KS (Stratagene, San Diego,
CA). Double-stranded dideoxynucleotide sequencing was performed
with Sequenase, as outlined by the manufacturer (United States
Biochemical Corp., Cleveland, OH), utilizing the KS and SK
' Abbreviations used in this paper: CDR, complementarity-determining
region; FR, framework; PC, phosphorylcholine.
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England Biolabs, Beverly, MA) . Approximately 3.7 kb of nucleo-
tide sequence was determined for each of the clones pIII-2 and
pII-13 from hybridomas 3A1 and CF2, respectively, with the aid
ofthe following primers : 5'd( TGC)3, 5'd(CCA
AAGCTGATGGCCCAGATG)3, 5'd(CTCTCCTTTCAGGAGT
CAGTGG)3, 5'd(GAGTGAA000TGAGGATGTG)3, 5'd(GAC-
CACGCTACCTGCAG)3, 5'd(TCTCCTTCTCTTCTCAG)3',
5'd(TTCCTACAGAGTCTCTC)3, 5'd(CTTGCT000CGTGG-
ACC)3', 5'd(TTCCTATCACTGTGTCCTCAGG)3, 5'd(GTA-
GTCTGTCACATCTC)3', 5'd(GCCAGCAAAAGTCATGG)3',
5'd(T000TGCCAAAGGCAAC)3, 5'd(TACTACCTCTGTCA
CCC)3', 5'd(GACT000AAACATCAGG)3, 5'd(GAG000TT
CCTTGTTAC)3, 5'd(GCCACTCACAAGACA)3'.
Results and Discussion
To assess the nature and distribution of somatic mutations
introduced into is transgenes, genomic transgene clones known
to contain V region substitutions, which had been isolated
from three different splenic B cell hybridomas (16), were fur-
ther examined . The history of the hybridomas is described
in Materials and Methods . Transgenes were cloned from the
genomic DNA of the hybridomas as 4.8-kb BarnHI frag-
ments spanning from within the leader-Va intron to 3' of
Crc (Fig. 1) . The entire 4.8 kb of clone pI-7 (isolated from
hybridoma CE9) was subcloned and sequenced . The region
sequenced included most of the leader-Vu intron (315 bp),
the entire V region, the Jas-Crc intron, the Ca gene, and
-1.3 kb 3' of the C gene. A total of 27 nucleotide substitu-
tions were identified based on thepublished germline sequence
(Fig . 2) . Ofthese, 15 were somatic mutations already present
in the MOPC-167 a gene used tomake the transgenc mice.
Thus, the pl-7 clone contains 12 new nucleotide substitu-
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tions . Two mutations are present in the leader-Vu intron, 6
in theV region (three ofwhich had previously been identified;
reference 16), and four within 500 by adjacent to the V gene
in the J5-Ca intron . Thus, 50% of the mutations occurred
outside coding regions. Five of the six V region mutations
are present in framework (FR) regions. Furthermore, all of
these nucleotide substitutions result in amino acid replace-
ments. The mutations at positions 561, 582, and 585 inFR1
result in changes from threonine to serine, proline to argi-
nine, and valine to glycine, respectively. The base change at
position 693 in FR2 replaces proline with leucine . The mu-
tation at position 767 in FR3 leads to substitution of threo-
nine with alanine. Many of these amino acid residue changes
represent significant replacements within the framework re-
gions of the V gene and could be potentially deleterious to
the production of a functional antibody molecule. In fact,
the sole nucleotide substitution present within a complemen-
tarity-determining region (CDR) is at position 658, and it
results in the introduction ofa translational termination codon .
Thus, this is transgene no longer retains the capacity to pro-
duce a functional a protein .
Sequencing of genomic clone pII-13 (isolated from hy-
bridoma CF2) was initiated 275 bases upstream of theV re-
gion and extended through the 3' untranslated region ofCa
(N3.7 kb) . A total of 21 nucleotide substitutions were ob-
served in addition to the marker mutations present in the
transgene (Fig. 2) . Five mutations are present in the leader-
Va intron, six within the V region (three of which were
previously identified ; reference 16), and 10 in the Ja5-Ca in-
tron. Based on this analysis, 71% of the newly introduced
mutations are outside of the coding regions. Three of the
six mutations found in the V region are in FR regions. Of
these, the nucleotide substitution at position 591 inFR1 results
Figure 1 .
￿
Localization of
nucleotide substitutions in a trans-
genes. The coding regions (Va167-
Je5) and Cic are boxed . Also
shown are the matrix association
region (MAR) and the kappa en-
hancer (Ex) . Lines extending
below the genes indicate marker
mutations already present in the
microinjected gene. Lines ex-
tending above the genes denote
newly introduced mutations .
Numbering is as in reference 23 .in the replacement of serine with phenylalanine. The substi-
tution at 556 in FRl is silent. The mutation at 789 in FR3
causes the introduction of threonine in the place of serine.
Both ofthe nucleotide substitutions within CDR3 are silent
mutations.
Genomic clone PIII-2 (isolated from hybridoma 3A1) was
sequenced from 270 by 5' of the V gene through the 3' un-
translated region of the CK gene. In the -3.7 kb sequenced,
four new nucleotide substitutions were observed (Fig. 2).'Of
the four mutations, only one is within the V region, so 75%
ofthe substitutions detected are outside ofcoding areas. The
mutation in the V gene is present within CDR3, but is silent.
The base substitution at position 838 was previously shown
to have arisen in the B cell from which hybridoma 3A1 was
derived. The mutation was detected in hybridoma 3A1 DNA,
but was absent from kidney (germline) DNA and thus was
a somatic event (16). The mutations at positions 942 and 1031
have since been shown to be somatic by sequence compar-
ison ofpolymerise chain reaction-amplified kidney and 3A1
hybridoma DNA (data not shown). Whether the base sub-
stitution at position 390 represents a somatic mutation is cur-
rently being determined.
Thus, a total of 37 new mutations have been identified
within the three K transgenes analyzed. No mutations were
found to be in common between the transgenes. Further-
more, no insertions or deletions were observed in any of the
cloned transgenes.
Examination ofthe overall distribution ofmutations within
the rearranged K transgenes reveals that they are localized to
the V region and its flanking sequences (Fig. 1). Although
we do not know the 5' boundary of the mutations, the
majority of theJtc5-Cu intron mutations are within 500 by
3' ofthe V region, beyond which the frequency ofmutations
is significantly reduced. The 3' most mutation observed (po-
sition 1708, pII-13) was <1 kb from the V region. The nu-
clear matrix association region (18) and the K transcriptional
enhancer located upstream of the C region are spared. No
mutations were detected in the C gene or the 3' untranslated
region. In fact, analysis ofclone pl-7 revealed that no muta-
tions were present as far as 1.3 kb 3' of the C region. To
our knowledge this represents one of the most complete anal-
yses of somatic mutations across an Ig gene. Consequently,
we have been able to precisely define the 3' boundary of the
mutations introduced into these is transgenes. The range of
newly introduced mutations in the "recycled" K transgenes
is very similar to that reported for endogenous Ig genes (3,
4, 19-21). Furthermore, the transgene itself had been mu-
tated in the B cell (myeloma) from which it was originally
cloned (22, 23); the newly introduced mutations are very
similar in distribution (Fig. 1) and nature (Table 1). While
it is not possible to formally show that the same mechanism
is responsible for the hypermutation of the K transgenes and
endogenous Ig genes, we have no evidence against a common
mechanism. Even though the Ktransgenes differ with respect
to chromosomal location from endogenous Ig genes, proper
targeting of the "mutator" is maintained. This suggests that
features responsible for targeting the mutations to a rearranged
Ig gene are present within the K transgene.
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* Mutations that were already present in the myeloma MOPC-167.
The precise mechanism responsible for introducing somatic
mutations is unknown. Ofinterest, a large number ofmuta-
tions were found in the Jtc5-Crc intron of these K transgenes.
This distribution is consistent with the available data con-
cerning the localization ofsomatic mutations outside V regions
in endogenous Ig genes (3, 4, 21) . These findings are not
easily reconciled with a gene conversion mechanism. The fre-
quency ofmutations does not seem to be related to the tran-
scriptional activity of the B cell hybridoma; the level of steady-
state transgenec KmRNA was approximately the same in all
three hybridomas (24). Furthermore, in the case ofhybridoma
3A1, mutated and unmutated transgenes appeared to be tran-
scribed equally well (16). Thus, at this time, no link can be
made between the mutation process and transcription of its
target gene.
Data concerning the nature of the substitutions identified
in the transgenes are presented in Table 1. A composite of
the K transgenes reveals that transitions and transversions occur
at approximately equal frequency. This holds true whether
assessed for the entire genes or, in order to bypass possible
selective pressures, for only silent changes and substitutions
within the introns. The T --> C transition is the only inter-
change that was not observed, but this transition has been
seen in other mutated Ig genes (25).
The frequency ofmutations introducedinto the V regions
of the transgenes pl-7 and pII-13 is 1.7%, slightly higher
than the 1.1% seen in the MOPC-167 K gene. The frequency
for pIII-2 is -0.3%. Of the cloned transgenes, the overall
number of mutations observed in pIII-2 is reduced as well.
Table 1. Newly
Substitutions
Introduced
VC167*
Mutations in
pI-7
the K Transgenes
pII-13 pIII-2
Transitions
A-G 3 1 5
G-A 3 1 6
C-"T 3 2 1
T-C - - -
Total 9 4 12 0
Transversions
C-A - - - 1
G-"T - - 1 -
A-C 3 - 3 1
A-T 1 - - -
G-C - 2 4 2
C-"G - 3 - -
T-A 1 - 1 -
T--"G 1 3 - -
Total 6 8 9 4GGATCCTTCT GATGCAGATG TAGATTCAGG TGCTGTTCAT TCCTGAGAAT ACTAGTTTTG CTTGACAGGC ATGTATCACT 301
----- ---------- ---------- ----------
---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
__________ _________A __________ __________
GAGGTGTCCT GGATGAACCT AGACTTTTGT GGCTATCCTT ACAACTACCA AAGCTGATGG CCCAGATGAT TCCTAGAGAG 381
---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
_____C____ __________ __________ _C________ __________ __________ __________ ----------
--A_______ __________ __________ __________ __________ __C_______ __________ __________
x x
TTTATATGCT CTCTTTACAT AGGTATTTTA TGTTGGGCGT TTTTGAAATG TTAATGAAGG TCATGAACAC AATAAGTAGG
________A_ __________ __________ __________ __________ __________ __________ __________
---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
__________ __________ __________ __________ _________A __________ __________ __________
AAATAAATAG AGGAAGGAAA AATCATATGA AAATACCATT GTGTTTGTGC ATACCTTTCA TTTCTCTCCT TTC GAGTC
---------- ---------- ---------- ---------- ---------- ---------- ----------
--- ------
_______ __________ __________ __________ __________ __________ __________ __
I
_
AGTGGGGATA TTGTGATAAC CCAGGATGAA CTCTCCAATC CTGTCACTTC TGGAGAATCA GTTTCCATCT CCTGCAGGTC
---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
__________ ---------G __________ __________ G__G______ __________ __________ __________
__________ ____A___
￿
__________ __________ ________T __________ __________ __________
TAGTAAGAGT CTCCTATATA AGGATGGGAA GACATACTTG AATTGGTTTC TGCAGAGACC AGGACAATCT CCTCAGCTCC
---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
__________ __________ __________ -----Ur__ __________ __________ __________ _T________
---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
TGATCTCTTT GATGTCCACC CGTGCCTCAG GAGTCTCAGA CCGGTTTAGT GGCAGTGGGT CAAGAACAGA TTTCACCCTG
---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
__________ __________ __________ __________ __________ __________ _____G____ __________
---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
*
GAAATCAGTC GAGTGAAGGC TGAGGATGTG GGTGTGTATT ACTGTCAACA ACTTGTAGAG TATCCGCTCA CGTTCGGTGC
__________ __________ __________ __________ _______:__ ______C___ __________ __________
---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
_______C__ __________ __________ __________ __________ _________A _____A____ __________
TGGGACCAAG CTGGAGCTGA AAC
---------- ---------- ---
---------- ---------- ---
---------- ---------- ---
PTAAGTA CACTTTTCTC ATCTTTTTTT ATGTGTAAGA CACAGGTTTT CATGTTAGGA
------ ---------- ---------- ---------- ---------- ---------- ______ __________ __________ __________ T_________ __________
'r______ __________ __________ ______GC__ __________ __________
__________ __________ __________ __________ __________ _______G__ __________ __________
__________ _______C__ __________ _________T __________ __________ __________ __________
x
GTTTATCAAG CTAGTGAGAT TAGGGGCAAA AAGAGGCTTT AGTTGAGAGG AAAGTAATTA ATATTATGGT CACCATCCAA
_________C __________ __________ __________ __________ __________ __________ __________
__________ __________ G_________ __________ __________ __________ __________ __________
__________ __________ _____C____ __________ __________ __________ __________ __________
---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
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461
541
621
701
781
861
941
GTTAAAGTCA GTTCAGAAAA TCTTGAGAAA ATGGAGAGGG CTCATTATCA GTTGACGTGG CATACAGTGT CAGATTTTCT 1021
1101
GAGATTGGAT CGGAGAATAA GCATGAGTAG TTATTGAGAT CTGGGTCTGA CTGCAGGTAG CGTGGTCTTC TAGACGTTTA' 1181
---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
AGTGGGAGAT TTGGAGGGGA TGAGGAATGA AGGAACTTCA GGATAGAAAA GGGCTGAAGT CAAGTTCAGT TCCTAAAAGG 1261
---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
__________ __________ __________ __________ _____A____ __________ __________ __________
__________ __________ __________ __________ __G_______ __________ __________ __________
*
GATGTGGGAG TAAACTTTGA AGATAAACTG AATGACCCAG AGGATGAAAC AGCGCAGATC AAAGAGGGGC CTAGAGCTCT 1341
---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------GAGAAGAGAA GGAGACTCAT CCGTGTTGAG TTTCCACAAG TACTGTCTTG AGTTTTGCAA TAAAAGTGGG ATAGCAGAGT 1421
---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
TGAGTGAGCC GTAGGCTGAG TTCTCTCTTT TGTCTCCTAA GTTTTTATGA CTACAAAAAT CAGTAGTATG TCCTGAAATA 1501
---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
__________ __________ __________ ________G_ __________ __________ __________ _____
*
￿
t
ATCATTAAGC TGTTTGAAAG TATGACTACT TGCCATGTAG ATACCATGGC TTGOTGAATA ATCAGAAGAG GTGTGACTCT 1581
---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
__________ __________ __________ __________ __________ __________ __________ _____G____
TATTCTAAAA TTTGTCACAA AATGTCAAAA TGAGAGACTC TGTAGGAACG AGTCCTTGAC AGACAGCTGC AAGGGGTTTT 1661
---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
TTTCCTTTGT CTCATTTCTA CATGAAAGTA AATTTGAAAT GATCTTTTTT ATTATAAGAG TAGAAATACA GTTGGGTTTG 1741
---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
__________ __________ __________ __________ ______A___ __________ __________ ----------
AACTATATGT TTTAATGGCC ACGGTTTTGT AAGACATTTG GTCCTTTGTT TTCCCAGTTA TTACTCGATT GTAATTTTAT 1821
---------- ---------- ---------- ---------- --------- ---------- ---------- ----------
---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
x
ATCGCCAGCA ATGGACTGAA ACGGTCCGCA ACCTCTTCTT TACAACTGGG TGACCTCGGC TGTGCCAGCC ATTTGGCGTT 1901
---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
CACCCTGCCG CTAAGGGCCA TGTGAACCCC CGCGGTAGCA TCCCTTGCTC CGCGTGGACC ACTTTCCTGA GGCACAGTGA 1981
---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
TAGGAACAGA GCCACTAATC 2001
---------- ----------
---------- ----------
---------- ----------
Figure 2.
￿
Nucleotide sequence of rearranged MOPC-167 a gene beginning at position 222 of the germline sequence (23). Comparison of the
MOPC-167 a gene sequence with the Ja5-Ca intron germline sequence (19, 28, 29) confirmed differences previously observed by Gearhart and
Bogenhagen (3), and revealed further alterations. The nature of the changes and their positions are listed below. Changes from the published se-
quence, including previously undetermined sequences, denoted as X in reference 28, are as follows: at position 1428, TX-deleted (del); 1435,
X = GGCTG; 1443, A = del; 1444, A = del; 1463, A = del; 1637, C = del; 1706, X = del; 1758, X = del; 1762, XC = del; 1832,
X = A; 1847, XXXXXX = C; 1860, G = del; 1865, T = del; 1878, T = del; 1913, X - TAAG; 1921, X = del; 1940, XX = CAT 1974,
A = del. We do not know whether the observed alterations represent errors in the published sequence or somatic mutations that occurred in
MOPC-167. However, in all cases, the insertions and deletions were common to all of the cloned transgenes. The Va167Ja5 coding region is
boxed, and complementarity-determining regions (30) are underlined. FRI begins at position 548. The Jas segment begins at position 848. Se-
quence analysis of pIII-2 and pII-13 begin at position 267 and 262, respectively. Nucleotide substitutions already present in the MOPC-167 a
gene are indicated by asterisks. Base substitutions in the cloned transgenes pIII-2, pl-7, and pII-13 are identified. Mutations resulting in amino
acid replacements are underlined. The nucleotide substitution that gave rise to a termination codon is boxed.
Clones pI-7 and pII-13 were isolated from hybridomas gener-
ated from a line carrying 13 copies ofthe is gene, whilepIII-2
was cloned from a hybridoma generated from a line with
three copies of the K gene. Whether there are consistently
fewermutations introduced into a transgenes in B cells from
the three copy line is currently being investigated.
The analysis of somatic mutation through the use of Ig
transgenes provides an opportunity not only to examine the
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minimal elements required for targeting of the "mutator"
but also to examine its specificity for V and surrounding
regions. Is the observed V region localization a result of selec-
tive pressures to produce intact C regions, or alternatively,
a reflection ofthe inherent specificity of the mutator mecha-
nism? The presence ofmultiple copies ofthe transgene might
be expected to reduce the selective pressure on any given copy
within the array, because introduction of mutations leadingto a loss of function of one copy would be compensated for
by the presence of other functional copies. Whereas a normal
B cell may be unable to tolerate a mutation leading to a loss
in surface Ig, in a transgenic mouse, expression of multiple
copies of an Ig transgene would allow for continued survival
of a transgenic B cell. In fact, evidence has been obtained
that multiple copies of the tc transgenes are transcribed (16,
24). Even under these conditions, mutations are highly local-
ized to the V regions.
Furthermore, analysis ofclone pI-7 from CE9 revealed the
presence of a stop codon in the V region. Clearly, we have
no way of knowing when the stop codon was introduced.
However, the continued production of transgenic K by hy-
bridoma CE9 (24) in conjunction with the high ratio of
FR/CDR (5 :1) mutations and the high (5:0) replacement/
substitution ratio observed in the FR regions of pI-7 is con-
sistent with the notion of reduced selective pressure on this
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